Targeting TNF-alpha for cancer therapy.
As the tumor vasculature is a key element of the tumor stroma, angiogenesis is the target of many cancer therapies. Recent work published in BMC Cell Biology describes a fusion protein that combines a peptide previously shown to home in on the gastric cancer vasculature with the anti-tumor cytokine TNF-alpha, and assesses its potential for gastric cancer therapy.
Montefiore Medical Center, Medical Arts Pavilion, 3400 Bainbridge Avenue, MMC-MAP, Bronx, NY 10467, USA.
Elizabeth R
ER
Burton
Steven K
SK
Libutti
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D016503:Drug Delivery Systems; D004730:Endothelium, Vascular / Q000187:drug effects; D015972:Gene Expression Regulation, Neoplastic; D015316:Genetic Therapy; D006801:Humans; D051379:Mice; D009369:Neoplasms / Q000628:therapy; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000517:prevention & control; D034741:RNA, Small Interfering / Q000627:therapeutic use*; D015398:Signal Transduction / Q000187:drug effects; D013274:Stomach Neoplasms / Q000628:therapy; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000235:genetics
D020533:Angiogenesis Inhibitors; D034741:RNA, Small Interfering; D014409:Tumor Necrosis Factor-alpha